BofA analyst Joanna Gajuk lowered the firm’s price target on Select Medical (SEM) to $18 from $22 and keeps a Buy rating on the shares. The firm lowered its price target citing a lower multiple given the continued pressures in the Critical Illness Recovery Hospitals, but believes that Inpatient Rehab Facility strength provides offsets while final Medicare regulation points to the pressure lessening starting in Q4.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM:
- Select Medical Updates Bylaws for Proxy Compliance
- Select Medical price target lowered to $14 from $15 at UBS
- Select Medical: Buy Rating Affirmed on Strong Financial Performance and Growth Prospects
- Select Medical Reports Strong Q2 2025 Earnings
- Select Medical’s Earnings Call: Growth Amid Challenges